Psychotherapy With Somatosensory Stimulation for Endometriosis-Associated Pain A Randomized Controlled Trial

被引:56
|
作者
Meissner, Karin [1 ]
Schweizer-Arau, Annemarie
Limmer, Anna
Preibisch, Christine
Popovici, Roxana M.
Lange, Isabel
de Oriol, Barbara
Beissner, Florian
机构
[1] Ludwig Maximilians Univ Munchen, Inst Med Psychol, Goethestr 31, D-80336 Munich, Germany
来源
OBSTETRICS AND GYNECOLOGY | 2016年 / 128卷 / 05期
关键词
SEXUAL ABUSE; PELVIC PAIN; WOMEN; MEDICINE; HISTORY;
D O I
10.1097/AOG.0000000000001691
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To evaluate whether psychotherapy with somatosensory stimulation is effective for the treatment of pain and quality of life in patients with endometriosis-related pain. METHODS: Patients with a history of endometriosis and chronic pelvic pain were randomized to either psychotherapy with somatosensory stimulation (ie, different techniques of acupuncture point stimulation) or wait-list control for 3 months, after which all patients were treated. The primary outcome was brain connectivity assessed by functional magnetic resonance imaging. Prespecified secondary outcomes included pain on 11-point numeric rating scales (maximal and average global pain, pelvic pain, dyschezia, and dyspareunia) and physical and mental quality of life. A sample size of 30 per group was planned to compare outcomes in the treatment group and the wait-list control group. RESULTS: From March 2010 through March 2012, 67 women (mean age 35.6 years) were randomly allocated to intervention (n=35) or wait-list control (n=32). In comparison with wait-list controls, treated patients showed improvements after 3 months in maximal global pain (mean group difference -2.1, 95% confidence interval [CI] -3.4 to -0.8; P=.002), average global pain (-2.5, 95% CI -3.5 to -1.4; P<.001), pelvic pain (-1.4, 95% CI -2.7 to -0.1; P=.036), dyschezia (-3.5, 95% CI -5.8 to -1.3; P=.003), physical quality of life (3.8, 95% CI 0.5-7.1, P=.026), and mental quality of life (5.9, 95% CI 0.6-11.3; P=.031); dyspareunia improved nonsignificantly (-1.8, 95% CI -4.4 to 0.7; P=.150). Improvements in the intervention group remained stable at 6 and 24 months, and control patients showed comparable symptom relief after delayed intervention. CONCLUSION: Psychotherapy with somatosensory stimulation reduced global pain, pelvic pain, and dyschezia and improved quality of life in patients with endometriosis. After 6 and 24 months, when all patients were treated, both groups showed stable improvements.
引用
收藏
页码:1134 / 1142
页数:9
相关论文
共 50 条
  • [41] Mifepristone for intractable endometriosis-associated pelvic pain
    Howard, Fred M.
    Ginde, Savita
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 68S - 68S
  • [42] Changes in Pain Sensitization During a Clinical Trial of OnabotulinumtoxinA for Endometriosis-Associated Chronic Pelvic Pain
    Karp, B. I.
    Salmeri, N.
    Shah, J. P.
    Sinaii, N.
    Tandon, H. K.
    Phan, V. Y.
    Aredo, J. V.
    Stratton, P.
    TOXICON, 2024, 237 : 38 - 39
  • [43] Medical Treatments for Endometriosis-Associated Pelvic Pain
    Zito, Gabriella
    Luppi, Stefania
    Giolo, Elena
    Martinelli, Monica
    Venturin, Irene
    Di Lorenzo, Giovanni
    Ricci, Giuseppe
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [44] Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial
    Trummer, Dietmar
    Walzer, Anja
    Groettrup-Wolfers, Esther
    Schmitz, Heinz
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2017, 96 (06) : 694 - 701
  • [45] Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study
    Acs, Nandor
    O'Brien, Chris
    Jiang, Ping
    Burke, Joshua
    Jimenez, Roland
    Garner, Elizabeth
    Chwalisz, Kristof
    JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, 2015, 7 (02) : 56 - 62
  • [46] Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial
    Donnez, Jacques
    Taylor, Hugh S.
    Taylor, Robert N.
    Akin, Mark D.
    Tatarchuk, Tatyana F.
    Wilk, Krzysztof
    Gotteland, Jean-Pierre
    Lecomte, Veronique
    Bestel, Elke
    FERTILITY AND STERILITY, 2020, 114 (01) : 44 - 55
  • [47] LINZAGOLIX FOR ENDOMETRIOSIS-ASSOCIATED PAIN: SAFETY RESULTS FROM EDELWEISS 3, A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Donnez, J.
    Taylor, H.
    Gemzell-Danielsson, K.
    Catherino, W.
    Bestel, E.
    Gotteland, J. P.
    Humberstone, A.
    Moore, L.
    Garner, E.
    HUMAN REPRODUCTION, 2022, 37 : I111 - I111
  • [48] Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study
    D'Hooghe, Thomas
    Fukaya, Takao
    Osuga, Yutaka
    Besuyen, Robin
    Lopez, Beatriz
    Holtkamp, Gertjan M.
    Miyazaki, Kentaro
    Skillern, Laurence
    HUMAN REPRODUCTION, 2019, 34 (05) : 813 - 823
  • [49] PRODUCTIVITY GAINS ASSOCIATED WITH TREATMENT WITH ELAGOLIX FOR ENDOMETRIOSIS-ASSOCIATED PAIN
    Diamond, M.
    Soliman, A. M.
    Snabes, M. C.
    Keith, G.
    Wang, H.
    Coddington, C.
    VALUE IN HEALTH, 2018, 21 : S144 - S144
  • [50] Ohnut vs waitlist control for the self-management of endometriosis-associated deep dyspareunia: a pilot randomized controlled trial
    Wahl, Kate
    Orr, Natasha L.
    Parmar, Gurkiran
    Zhang, Sandy X. J.
    Macleod, Rebecca G. K.
    Noga, Heather
    Albert, Arianne
    Flannigan, Ryan
    Brotto, Lori A.
    Yong, Paul J.
    SEXUAL MEDICINE, 2024, 12 (04)